Free Trial
NASDAQ:VTYX

Ventyx Biosciences Q4 2023 Earnings Report

Ventyx Biosciences logo
$2.56 +0.07 (+2.81%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$2.55 -0.01 (-0.39%)
As of 06/13/2025 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ventyx Biosciences EPS Results

Actual EPS
-$0.79
Consensus EPS
-$0.87
Beat/Miss
Beat by +$0.08
One Year Ago EPS
-$0.62

Ventyx Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ventyx Biosciences Announcement Details

Quarter
Q4 2023
Time
After Market Closes
Conference Call Date
Tuesday, February 27, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Ventyx Biosciences' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Ventyx Biosciences Earnings Headlines

Ventyx Biosciences reports annual meeting results
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Ventyx Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ventyx Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ventyx Biosciences and other key companies, straight to your email.

About Ventyx Biosciences

Ventyx Biosciences (NASDAQ:VTYX), a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

View Ventyx Biosciences Profile

More Earnings Resources from MarketBeat